Antibody-Drug Conjugates in Ovarian Cancer: Promises and Challenges
Ovarian cancer (OC) remains one of the most lethal gynecological malignancies globally, often detected at advanced stages which contribute to its high mortality rate. Recurrent and drug-resistant cases further complicate the therapeutic landscape, underscoring the urgent need for innovative treatmen...
Saved in:
| Main Authors: | Marta Nerone, Maria Del Grande, Ilaria Colombo |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-10-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2023.17.119 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Antibody-Drug Conjugates in Solid Tumors
by: Ilaria Colombo, et al.
Published: (2022-03-01) -
Immune Checkpoint Inhibitors in Endometrial Cancer: The New Paradigm of Treatment for Advanced and Recurrent Disease
by: Marta Nerone, et al.
Published: (2023-12-01) -
Antibody-Drug Conjugates in Cancer
by: Marcus Vetter
Published: (2024-06-01) -
Improved targeting of an anti‐TAG‐72 antibody drug conjugate for the treatment of ovarian cancer
by: Megan Minnix, et al.
Published: (2020-07-01) -
Antibody drug conjugates in the clinic
by: Edidiong Udofa, et al.
Published: (2024-11-01)